The screening has confirmed the variability of AChE inhibitors on modulating AD features, whilst suggesting that a dual GSK-3/AChE inhibition strategy could be a potential route for the development of an AD therapy with potential disease-modifying properties. Here, ACHE is linked to Alzheimer disease.